The FDA has expanded the label of Abilify Maintena (aripiprazole), from Otsuka, for extended-release injectable suspension to include a new...
Otsuka and Lundbeck received a positive recommendation the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on...
Lundbeck and Otsuka announced marketing authorisation approval from the European Commission for Abilify Maintena (aripiprazole), an intramuscular (IM) once-monthly injectable...
The FDA has approved the labeling update of Abilify Maintena (aripiprazole), from Otsuka/Lundbeck, for extended-release injectable suspension in patients with...
H. Lundbeck A/S and Otsuka Pharmaceutical Europe Ltd. announced results from the final analysis of a mirror-image study showing statistically...
H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. have announced that the FDA has on 28 February 2013 approved Abilify...
H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. announced the FDA has determined that the supplemental New Drug Application (sNDA)...
Lundbeck and Otsuka Pharmaceutical Co announced Abilify Maintena (aripiprazole) for extended-release injectable suspension was approved by the FDA for the...
Otsuka America Pharmaceutical and Lundbeck announced results from the QUALIFY study, the first study of its kind comparing the effectiveness...
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S announced that the European Commission (EC) has approved Abilify Maintena 960 mg (aripiprazole) as a once-every-two-months long-acting injectable (LAI) formulation for the maintenance treatment of schizophrenia in adult patients stabilised with aripiprazole.